Author

Alex T. Larsson

University of MinnesotaORCID 0000-0002-1350-8271Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

David A. LargaespadaiD· 4 shared Kyle Brandon WilliamsiD· 3 shared Zachary J. SeemaniD· 3 shared Chang-Jung LeeiD· 2 shared Christopher M. StehniD· 2 shared Tyler A. JubenvilleiD· 2 shared Wendy A. HudsoniD· 2 shared Adam J. DupuyiD· 1 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

David A. LargaespadaORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Biomarker-driven and gene-enhanced viral therapy for malignant peripheral nerve sheath tumor

Meghna Saxena, Love Li, Brady G. Strittmatter, Kyle Brandon Williams, Faruck Lukmanul Hakkim, Shraddha Potti, Alanna Halloran, Elsie Warren, Danielle N Maryanski, Courtney Barnes, Christopher M. Stehn, Madilyn R. Stahl, Chungchi Lee, Alex T. Larsson, Zachary J. Seeman, , Robert Thomas Galvin

This study develops a gene-enhanced HSV therapy for MPNST by exploiting PRC2 loss and tumor-regulated ICP34.5 expression to improve viral efficacy.

bioRxiv · Oct 14, 2026 · PreprintCancer Biology

Integrated ex vivo screening and transcriptomic profiling to prioritize drug combinations for rare cancers

Ritu C. Shah, Alex T. Larsson, Belinda B. Garana, Yang Lyu, Zachary J. Seeman, Elizabeth Rono, Kyle Brandon Williams, Dana C. Borcherding, Ke Xiao, Xiaochun Zhang, Yannick Mahlich, Jeremy Jacobson, Lisa B. Fridman, Yan Zhou, Christine A. Pratilas, , Sara J.C. Gosline

The paper develops EXACT, a framework combining ex vivo drug screening with transcriptomic analysis to identify effective drug combinations for rare cancers, finding a MEK and HDAC inhibitor combination shows enhanced activity.

bioRxiv · Jul 29, 2026 · PreprintCancer Biology

Sleeping Beauty mutagenesis identifies BACH2 and other regulators of CD8+T cell exhaustion, persistence in vivo, and CAR-T function under tumor-associated chronic antigen stimulation

Chang-Jung Lee, Alex T. Larsson, Tyler A. Jubenville, Wendy A. Hudson, Zachary J. Seeman, Carli M. Stewart, Alexander K. Tsai, Adam L. Burrack, Brooke L. Kimball, Elizabeth L. Siegler, Vianca V. Vianzon, Erin E. Nolan, Yu-Ling Yang, Christopher M. Stehn, Daryl M. Gohl, , David A. Largaespada

The paper uses Sleeping Beauty mutagenesis to identify BACH2 and other genes that enhance CD8+ T cell persistence and function under chronic antigen stimulation, improving engineered T cell therapies.

Journal for ImmunoTherapy of Cancer · Jul 1, 2026Peer-reviewedImmunology

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors

Kyle Brandon Williams, Alex T. Larsson, Bryant J. Keller, Katherine E. Chaney, Rory L. Williams, Minu M. Bhunia, Garrett M. Draper, Tyler A. Jubenville, Wendy A. Hudson, Gunda I. Georg, Christopher L. Moertel, Nancy Ratner, David A. Largaespada

This study identifies 23 compounds that selectively kill NF1-deficient Schwann cells and shows their efficacy in vivo, with synergy when combined with Selumetinib.

Molecular Cancer Therapeutics · Oct 1, 2025Peer-reviewedCancer Biology